IMRT plus Cetuximab Feasible and Safe in Elderly Patients with Stage III NSCLC

TOP - Daily - Lung Cancer

Radioimmunotherapy with intensity-modulated radiotherapy (IMRT) and cetuximab produced a overall response rate of 63% in patients with stage III non–small-cell lung cancer (NSCLC), in the phase 2 NEAR trial. Patients (median age, 71 years) received 1 loading dose of cetuximab 1 week before radiotherapy, followed by radioimmunotherapy (comprised of 7 weekly applications of cetuximab), and ending with 13 applications of maintenance cetuximab. Patients also received dexamethasone and dimetinden before each dose of cetuximab. Treatment was well tolerated (only mild toxicity). The researchers noted that although the feasibility and safety profile are encouraging, further research is needed to address the influence of histologic subtype.

 

The complete study is published in the July 1, 2011, issue of Cancer (http://onlinelibrary.wiley.com/doi/10.1002/cncr.25888/abstract;jsessionid=8E9E05F623E0B63C4642A081EA194747.d02t04?systemMessage=Wiley+Online+Library+will+be+disrupted+2+July+from+10-12+BST+for+monthly+maintenance).

Related Items
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: July 22, 2021